Biotech Values

[genisi]

I think we all agree that there won't be an automatic substitutability and some clinical trials will be required. The uncertainty is about what size&type of studies. Although a regulatory pathway requiring an abbreviated application is still a possibility, I think that for many Fob's phase III shaped studies would likely be needed to demonstrate therapeutic equivalence to the reference product.